Compare AFLAC Incorporated (AFL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs IDEXX Laboratories, Inc. — how do they compare? AFLAC Incorporated trades at $121.25 (market cap $61.84B), while IDEXX Laboratories, Inc. trades at $557.94 (market cap $44.98B). The key difference: AFLAC Incorporated is the larger of the two by market cap, and AFLAC Incorporated pays a 2.01% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| AFL | IDXX | |
|---|---|---|
Market Cap | $61.84B | $44.98B |
Sector | Financials | Health |
52-Week High | $121.49 | $766.68 |
52-Week Low | $98.09 | $514.61 |
Enterprise Value | $70.50B | $45.89B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
IDXX trades at $570.25, up 2.23% today, with strong technical momentum as it approaches resistance near $572. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics. Analyst sentiment is bullish with a $645 consensus target, though elevated valuations pose a risk.
Outlook remains positive given consistent earnings beats and strategic AI integration, but high P/E of 41.57 suggests limited margin for error. Key risks include competitive pressures and reliance on pet healthcare spending cycles. Institutional ownership trends and upcoming Q2 earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
